Exicure, Inc. Common Stock (XCUR) Stock Price

XCURStock

$1.29−77.01%52W

Market Cap$8.44M

P/E—

PEG Ratio—

Div yield—

Beta3.75

XCUR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-76.00%

Price vs S&P 500 (4W)-19.90%

VGM Score30.39

Book Value / Share (Quarterly)$0.33

P/TBV (Annual)242.39x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.27

Price vs S&P 500 (YTD)-89.02%

Net Profit Margin (TTM)-165.80%

EPS (TTM)$-1.54

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-1.54

Revenue Growth (5Y)-17.40%

EPS (Annual)$-0.79

ROI (Annual)-125.98%

Net Profit Margin (5Y Avg)-4559.15%

Cash / Share (Quarterly)$0.41

ROA (Last FY)-35.23%

EBITD / Share (TTM)$-1.33

ROE (5Y Avg)-283.38%

Operating Margin (TTM)-167.20%

Cash Flow / Share (Annual)$-1.34

P/B Ratio3.95x

P/B Ratio (Quarterly)12.93x

Net Income / Employee (Annual)$-618,200

EV / Revenue (TTM)11.36x

Net Interest Coverage (TTM)-1937.60x

ROA (TTM)-64.37%

EV / EBITDA (TTM)0.95x

EPS Incl Extra (Annual)$-0.79

Current Ratio (Annual)1.19x

Quick Ratio (Quarterly)0.65x

3-Month Avg Trading Volume0.29M

52-Week Price Return-77.01%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.02

P/S Ratio (Annual)16.57x

Asset Turnover (Annual)0.03x

52-Week High$9.48

Operating Margin (5Y Avg)-4551.11%

EPS Excl Extra (Annual)$-0.79

CapEx CAGR (5Y)-80.06%

Tangible BV CAGR (5Y)-5.67%

26-Week Price Return-64.07%

Quick Ratio (Annual)1.04x

13-Week Price Return-56.57%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.79x

Enterprise Value$5.68M

Revenue / Share Growth (5Y)-18.42%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)-50.73%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1938.60%

Cash / Share (Annual)$0.59

3-Month Return Std Dev107.00%

Net Income / Employee (TTM)$-1,223,000

ROE (Last FY)-125.98%

Net Interest Coverage (Annual)-391.44x

EPS Basic Excl Extra (Annual)$-0.79

Receivables Turnover (TTM)-49.20x

EV / Free Cash Flow (TTM)0.48x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.54

ROI (TTM)-179.41%

P/S Ratio (TTM)16.57x

Pretax Margin (5Y Avg)-4558.68%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.02

Price vs S&P 500 (52W)-95.56%

Year-to-Date Return-76.20%

5-Day Price Return12.17%

EPS Normalized (Annual)$-0.79

ROA (5Y Avg)-71.11%

Net Profit Margin (Annual)-1940.20%

Month-to-Date Return-19.38%

Cash Flow / Share (TTM)$0.67

EBITD / Share (Annual)$-0.58

Operating Margin (Annual)-2365.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-239.74%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.54

P/TBV (Quarterly)242.39x

P/B Ratio (Annual)8.77x

Pretax Margin (TTM)-165.80%

Book Value / Share (Annual)$0.62

Price vs S&P 500 (13W)-58.52%

Beta3.75x

P/FCF (Annual)34.52x

Revenue / Share (TTM)$0.00

ROE (TTM)-179.41%

52-Week Low$1.05

vGradeC

gGradeF

mGradeD

vgmGradeD

XCUR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2022	Aug 15, 2022	-$6.00	-$8.30	-38.33%(-$2.30)
Q1 2022	May 16, 2022	-$10.50	-$10.50	+0.00%(+$0.00)
Q4 2021	Mar 25, 2022	-$21.00	-$22.50	-7.14%(-$1.50)
Q3 2021	Nov 19, 2021	-$22.50	-$40.50	-80.00%(-$18.00)

XCUR Analyst Recommendations

Oct 2022

Nov 2022

Dec 2022

Jan 2023

2.17

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
XCURExicure, Inc. Common Stock	C	F	D	$1.29
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Exicure, Inc. Common Stock

Exicure Inc is an early-stage biotechnology company developing nucleic acid therapeutics targeting validated disease pathways. The company specializes in RNA-based therapeutic approaches to address unmet clinical needs.